SpecGx FDA Tuesday, October 6, 2020 0.00 Neutral

FDA Approves DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE — SpecGx LLC

SpecGx LLC has secured FDA approval for the generic oral formulation of Diphenoxylate Hydrochloride and Atropine Sulfate, positioning the company to enter the market and increase competition within the branded antidiarrheal segment. This clearance is expected to foster pricing pressure, thereby lowering costs and improving patient access to treatment.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day